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EDITORIALS
Reducing the length of time between HIV infection  
and diagnosis
Targeting high risk groups should remain the priority
In this week’s BMJ, two analysis articles about testing 
for HIV argue for changes in policy that would expand 
the number of people routinely tested by promoting 
opt-out approaches.1 2 Both papers argue that this would 
increase the proportion of the population who know 
their serostatus and would decrease the number of late 
diagnoses of HIV. The papers agree about the benefits 
of swift diagnosis of HIV, including reduced mortality 
and morbidity, less onward transmission because treat-
ment should reduce infectiousness, and reduced costs 
of acute treatment and lost productivity.
We argue that a more precise goal for any changes 
in policy should be to reduce the average time between 
HIV infection and diagnosis in people who become 
infected.3 This goal allows a range of measures of suc-
cess beyond a CD4 count below 200×106/l and acknowl-
edges that the earlier HIV is diagnosed the better.
As the secretary general of the United Nations 
highlights, improved epidemiological outcomes are 
dependent on people being able to test in “a social and 
legal environment that is supportive and safe.”2 This 
needs to apply equally to people who receive a negative 
result as those who do not. Many of the benefits of 
having HIV diagnosed are not available to people 
without legal status in the United Kingdom because of 
the costs of drugs and continuing care. In addition to 
questions of access to treatment, a diagnosis of HIV 
has implications for sexual and social relationships, 
especially in the light of criminal prosecutions for the 
reckless transmission of HIV.4
HIV is one of the most stigmatised diseases.5 This 
stigma is embedded in pre-existing social inequality, 
and it is disappointing that neither analysis article 
takes account of the extent to which racism, xenopho-
bia, and homophobia drive HIV related stigma. Huge 
increases in the number of people testing negative for 
HIV will not change those attitudes or the practices 
that maintain the social inequalities that reinforce HIV 
related stigma.
This call for expansion of routine opt-out HIV testing 
encompasses primary care and various acute settings.1 2 
However, studies in the UK show that health profession-
als in non-HIV specialist settings discriminate against 
people with HIV.5 6 Opt-out testing policies would exac-
erbate this, and substantial investment in training and 
staff support would be needed to foster a “safe and sup-
portive” environment as stipulated by the UN.
While calls for seroprevalence studies that are not 
linked to named individuals and a further examination 
of cost effectiveness are welcome,2 it is unclear what 
justification these could provide for expanded routine 
opt-out HIV testing. It is unlikely that the Centers for 
Disease Control (CDC) threshold for universal testing—
when there is a 0.1% prevalence of HIV in a given pop-
ulation7—would be reached in many healthcare settings. 
While opt-out HIV testing in antenatal care is widely 
regarded as a success, it did not reach this threshold 
in England and Scotland in 2005.8 Moreover, a recent 
analysis of CDC guidelines suggests that counselling 
and testing that is targeted at populations most likely 
to have undiagnosed HIV would diagnose more HIV 
infections, prevent more HIV infections, and do this at a 
lower cost for each infection averted than would opt-out 
testing without specific consent or pre-test discussion.9
In the UK in 2005, 20 100 people were assumed 
to have undiagnosed HIV.8 Most were assumed to 
be men who have sex with men (9000), African born 
heterosexuals (5400), or people who inject drugs 
(500). Only 4900 were thought to be non-African 
born heterosexuals who do not inject drugs. With a 
relatively small number of undiagnosed people in 
the population—mainly in groups where access to 
healthcare services can be problematic—expanding HIV 
testing provision across a range of settings is unlikely 
to be cost effective. If such an expansion requires the 
omission of pre-test discussion, then this conflicts with 
UK national guidelines on HIV testing, especially for 
people at highest risk, who constitute three quarters of 
those with undiagnosed HIV.10 It also conflicts with 
evidence from a CDC sponsored randomised control 
trial that interactive client centred counselling during 
HIV testing could reduce subsequent risk behaviour 
and the incidence of sexually transmitted infections.11
Since the publication of the national strategy for 
sexual health and HIV,12 uptake of HIV testing by 
people attending UK genitourinary medicine clinics has 
increased yearly. In 2005, 80% of men who have sex 
with men were tested, compared with 61% in 2001, and 
82% of heterosexuals were tested compared with 41%.8 
While some people with undiagnosed HIV still attend 
these clinics without being tested, the proportion of UK 
residents with undiagnosed HIV has fallen yearly as the 
proportion of people who are tested for HIV at a sexual 
health clinic has risen.
Factors that influence the offer and uptake of HIV test-
ing and whether patients return for the results include the 
sexual health clinic’s policy on HIV testing (opt-in or opt-
out)13 14 and how long people have to wait for results.15 
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Opt-out HIV testing is not a universal policy in geni-
tourinary medicine clinics in the UK, even for African 
migrants and men who have sex with men. Moreover, 
waiting times for appointments and HIV test results vary 
and point of care (rapid) testing is relatively rare.
These data show that the possibilities for targeting 
and diagnosing people at highest risk of HIV 
have not been exhausted. Intensified targeting is 
challenging but is essential for a major impact on 
the time between infection and diagnosis. If this 
strategy proves effective we could then consider 
how to encourage HIV testing in people who are 
less likely to have HIV.
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Ethics of collecting and using healthcare data
Primary responsibility lies with the organisations involved, not ethical review 
committees
Quality assurance is a broad concept that includes 
activities termed audit, quality improvement, and 
clinical governance.  Both quality assurance and 
research require the systematic collection and analysis 
of data from all (relevant) patients.  However, whereas 
research activities are generally required to undergo 
independent ethical review, audit activities are exempt 
from such review. How can we ensure that quality 
assurance activities are ethical?
Patients using any healthcare system have an ethical 
responsibility to help with quality assurance activities,1-3 
and with epidemiological research based on popula-
tion-wide databases, such as the United Kingdom’s new 
National Health Service programme,4 because they will 
benefit from such activities.  However, involvement in 
quality assurance and epidemiological research usually 
involves using patients’ data without their consent. In 
return for this loss of autonomy and potential risk (of 
disclosing information that might harm), patients should 
expect quality assurance activities to be ethically sound, 
healthcare resources to be committed to quality assur-
ance, and benefits to justify any risks and burdens.
Two national working parties, in the United States 
and Australia, have considered the ethics of quality 
assurance activities.2 3 The US Hastings Center report 
considers that research activities can be distinguished 
from quality assurance and suggests that organisations 
take responsibility for the ethics of their own quality 
assurance.2 5 6 In contrast, the Australian report agrees 
with many others that the distinction is not possible, and 
it suggests that research ethics committees should be 
approached when potential ethical problems exist. 3 6 7
Data protection laws make the resolution of this 
problem urgent. Quality assurance may be stopped,2 8 
unethical activities may occur,8 9 and research may be 
relabelled as quality assurance to avoid scrutiny, espe-
cially because the existing research ethics framework is 
becoming increasingly overwhelmed, often delaying or 
preventing research.10
The ethical problem associated with the collection 
and use of data for non-clinical purposes relates to the 
relationship between patients as a group and organi-
sations (such as clinical teams, whole hospitals). It is 
assumed that most ethical issues will arise in the context 
of research, while other activities in healthcare organisa-
tions are automatically ethical. This assumption has led 
to attempts to categorise research separately from other 
activities.11 However, these assumptions are invalid; 
healthcare organisations are no more or less likely than 
researchers to pursue ethically dubious activities. We 
should therefore ask ourselves how to ensure that the 
collection and analysis of data from patients within 
health care is carried out ethically.
Collecting and using patient generated data, beyond 
simply making an individual clinical decision, is ethi-
cally sound only if there is (or could reasonably arise) 
a question to be answered; the methodology (design, 
data collected, etc) will answer the question; and the 
costs, including both communal healthcare resources 
and any risks and burden imposed on the participants, 
justify the benefits to society. Asking the questions in 
the box will help to identify the nature and extent of 
any ethical concern.
But who should ask the questions, and who should 
make the ethical judgment? The Hastings Center report 
argues convincingly that institutional review boards as a 
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single external ethical “hurdle” are an inappropriate way 
of achieving ethical standards in quality assurance.2
Instead, the authors recommend that “the primary 
responsibility for the ethical conduct of quality improve-
ment be lodged in individual organisations . . . [it] should 
be integrated into normal supervision and management, 
with the organisation’s leaders [being] responsible for 
seeing that the integration occurs and is effective.” 
There is no reason why this recommendation could not 
also apply to all activities within health care, including 
research.12
Ethically difficult situations that require independent 
help will still arise. Existing ethical review committees 
could provide independent advice,3 but only if their 
total workload is reduced. This could be achieved 
if ethical problems were considered in proportion 
to the importance of the ethical problem.3 6 7 12 We 
need an ethical ladder to lift us over problems, not 
an ethical hurdle to hinder people undertaking 
research. Organisations should have internal 
procedures for ensuring their activities are ethical, 
and they should seek external help only when it 
is needed.
Finally, we need to check that organisations are tak-
ing their ethical responsibilities seriously.2 The profes-
sional, personal, and organisational responsibilities for 
ethical behaviour should be made explicit, and organi-
sations need to incorporate ethical considerations into 
all management activities. Their performance of this 
duty should be reviewed by external monitoring and 
accrediting agencies.2
In summary, the ethical responsibility of systematic 
collection and analysis of patient data for any pur-
pose is the responsibility of the people and organisa-
tions involved. Internal organisational arrangements 
should allow most problems to be resolved but when 
they are complex or difficult, external help should be 
sought from an accredited source, such as ethics review 
boards. External accrediting organisations should audit 
ethical review procedures as they audit other aspects of 
an organisation.
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Questions to ask of any systematic data collection process in health care
Design
Will	the	method	answer	the	question	being	asked?
Process
How	much	will	each	participant	be	informed	about	the	study?
Will	each	participant	be	able	to	choose	whether	or	not	to	participate?
Will	the	method	of	recruiting	participants	be	fair?
Cost
What	organisational	resources	will	the	project	use?
What	extra	burden	will	be	imposed	upon	the	participant(s)?
What	additional	risks	will	the	participant(s)	face?
Benefit
What	benefit	might	accrue	to	the	participant(s)?
What	benefit	might	accrue	to	society?
BMJ 2007;334:1331-2
doi=10.1136/bmj.39252.524375.80
Lactose intolerance
Is common and can be diagnosed clinically and treated with simple dietary 
measures
Lactose intolerance occurs in about 25% of people in 
Europe; 50-80% of people of Hispanic origin, people 
from south India, black people, and Ashkenazi Jews; 
and almost 100% of people in Asia and American 
Indians.1 Lactose is a disaccharide sugar that is found 
exclusively in mammalian milk and is digested by 
the enzyme lactase in the mucosal brush border of 
the intestine. Reduced intestinal lactase results in 
malabsorption of lactose. The unabsorbed lactose is 
metabolised by colonic bacteria to produce gas and 
short chain fatty acids, causing the clinical syndrome 
of abdominal cramps, bloating, diarrhoea, and flatu-
lence. Lactose malabsorption does not always cause 
lactose intolerance; symptoms depend on the amount 
and rate of lactose reaching the colon, and the amount 
and type of colonic flora.
Lactase deficiency may be classified as primary, 
secondary, congenital, and developmental. The 
classification is important as it relates to diagnosis, 
prognosis, and treatment. In all mammals, lactase 
concentrations are at their highest shortly after birth 
and decline rapidly after the usual age of weaning. 
In people with primary lactase deficiency, such a 
physiological decline in lactase concentrations occurs 
at the age of weaning. This condition is a recessive 
inherited trait; the underlying genetic change is dif-
ferent in the European and African populations.2 3 
Secondary lactase deficiency results from injury to the 
CO
M
ST
O
CK
CO
M
PL
ET
E.
CO
M
EDITORIALS
1332	 	 	 BMJ | 30 June 2007 | VoluMe 334
small bowel mucosal brush border secondary to viral 
or non-viral intestinal infection. It is more common 
in children, particularly those in developing coun-
tries, where such infections are common. Congeni-
tal lactase deficiency is an extremely rare disorder 
that manifests at birth, soon after milk is introduced. 
Affected infants have minimal or absent lactase in an 
otherwise normal intestinal mucosa. Developmental 
lactase deficiency occurs in premature infants (<34 
weeks’ gestation), and rapidly improves as the intes-
tinal mucosa matures. 
Lactose intolerance should be suspected in people 
with abdominal symptoms after ingestion of milk 
and milk products. The symptoms can be disabling 
enough to interfere with daily life. Improvement in 
symptoms after eliminating such foods and worsen-
ing when they are reintroduced confirms the diag-
nosis. Diarrhoea is more pronounced in children 
with secondary lactase deficiency than in those with 
the primary form and may lead to dehydration and 
growth failure; perianal excoriations due to acidic 
stools are common. 
Several tests are available for the diagnosis of 
lactose malabsorption. The lactose tolerance test 
(reproduction of symptoms and rise in serum glucose 
by <1.11 mmol/l, 60-120 minutes after ingestion of 
50 g lactose) has a sensitivity of around 75%. The 
lactose hydrogen breath test (increase in hydrogen 
concentration in exhaled air to >20 parts per million 
after 20 g of lactose) is more sensitive.4 A breath test 
using carbon-13 labelled lactose and estimation of 
lactase in intestinal biopsy are also available. How-
ever, the diagnosis can be made easily on the basis 
of clinical history by general practitioners as well as 
specialists, and diagnostic tests are rarely needed in 
clinical practice. Differences in underlying genetic 
changes in different geographical regions may pre-
clude the development of a single DNA based diag-
nostic test.
Treatment depends on the underlying type of defi-
ciency. In primary lactase deficiency the develop-
ment of symptoms depends on how much lactose 
needs to be ingested before the available lactase is 
saturated. Thus, most people with primary lactase 
deficiency can ingest up to 240 ml of milk (12 g 
of lactose) without developing symptoms.5 It may 
help to divide daily milk intake into several small 
portions and to take it with other foods. Yoghurt, 
curds, and cheeses are better tolerated, because 
lactose is partially hydrolysed by bacteria during 
their preparation and gastric emptying is slower as 
these products have a thicker consistency. Lactase 
enzyme preparations—ingested directly or added to 
milk—and soya milk have been used.6 These are too 
costly for people in poorer countries, however, and 
are possibly unnecessary. Instead, people with lac-
tose intolerance should be encouraged to gradually 
increase their intake of milk—this causes changes in 
the intestine that permit higher milk intake.7 Milk 
is the main source of calcium in predominantly 
vegetarian communities, so ingestion of milk is 
important to avoid the increased risk of osteopenia, 
osteoporosis, and long bone fractures.8 Milk-cereal 
mixtures delay the entry of lactose into the intestine, 
permitting better absorption. Since these are cheap 
and easily prepared at home, their use should be 
promoted.
In secondary lactase deficiency, treatment is 
directed at the underlying cause. Short periods of lac-
tose intolerance are common after episodes of infec-
tive diarrhoea and may prolong the diarrhoeal illness. 
This can lead to unnecessary antimicrobial treatment 
and unwarranted avoidance of milk—a meta-analysis 
has shown that most children with acute diarrhoea 
can safely continue to receive breast or undiluted 
animal milk.9 This is particularly important in devel-
oping countries, where milk is a convenient, read-
ily available, and well accepted food of exceptional 
nutritional value. A randomised trial in malnourished 
children in India found that giving milk rather than 
yoghurt during acute diarrhoea was associated with 
higher milk intake and better weight gain and did not 
increase diarrhoea.10 Further randomised controlled 
trials have shown that milk-cereal mixtures given at 
frequent intervals (nearly 2 g/kg/day of lactose or 
40 ml/kg/day of milk) were well tolerated by most 
children with persistent diarrhoea.11 12
Lactose intolerance is a common condition that 
can be diagnosed on clinical history and treated with 
simple dietary measures. Most patients do not need 
referral to a specialist or diagnostic laboratory tests. 
Non-responders will benefit from reducing lactose 
intake below their current threshold of tolerance, 
followed by long term steps directed at improving 
adaptation of the intestine. 
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Performance measurement and equity
To maximise benefits and minimise harm, equity must be built in from the start
Performance measurement is now a reality for clinicians 
around the world. It involves measuring and monitoring 
quality of care using standardised indicators. Shortcom-
ings in the quality of care—the gap between what we 
know and what we do—are well documented.1 So too 
are inequities in access, quality, and outcomes linked to 
gender, ethnic origin, and socioeconomic status.2 Rec-
ognition of substandard and uneven quality of care has 
fuelled calls for providers to be more publicly account-
able and for health systems to change. 
Interest is growing in performance measurement as 
a way to drive improvements in health care. In this 
week’s BMJ, McDonald and colleagues describe an 
ethnographic case study in which two English general 
practices changed their organisation to achieve high 
performance scores under the quality and outcomes 
framework.3 The quality and outcomes framework, and 
other high profile measurement and reporting efforts 
such as those in the US Veterans’ Health Administra-
tion, have met with some early success.4 5 Adding to this 
enthusiasm is a recent study that attributes declining 
mortality from acute coronary syndromes and heart 
failure—two conditions in which performance measure-
ment has been widely used—to increased use of evi-
dence based treatments.6 However, optimism about 
potential benefits is tempered by growing concerns 
about potential harms.7
McDonald and colleagues were particularly con-
cerned with adverse effects on practitioners’ clinical 
autonomy and motivation. However, they found that 
incentives were mostly aligned with professional values 
about optimising quality of care. What the study does 
not tell us, though, is how these organisational changes 
were perceived by patients or what impact they had 
on patients from different communities in different 
practice settings.
 Socially disadvantaged patients may stand to benefit 
most from structured efforts to measure and improve 
quality, as they often experience the largest quality gaps. 
Importantly, however, they may also be at greatest risk 
of harm.8 Equity is a major dimension of healthcare 
quality and a key attribute of high performing health 
systems,9 so initiatives to improve quality will be 
incomplete unless inequities are reduced as perform-
ance improves. Performance measurement and quality 
improvement alone will not result in more equitable 
systems of care.
Interventions to improve quality can impact on health 
inequities in three ways: they may narrow, maintain, 
or widen existing inequities, depending on their rela-
tive effectiveness in different groups of people and 
how they deal with the root causes of inequity. In a 
randomised controlled trial, a complex intervention 
designed to improve the quality of primary care for 
depression reduced disparities by improving health 
outcomes and unmet need significantly more among 
Latinos and African Americans than among whites.10 A 
longitudinal study examined the impact of performance 
measurement for patients with end stage renal disease 
insured by Medicare in the United States. It found that 
racial and gender disparities were reduced in relation to 
the adequacy of haemodialysis but were unchanged for 
the management of anaemia and nutritional status.11 A 
retrospective analysis of performance data from Medi-
care managed care showed steady improvement over 
many years, with narrowing of disparities in process 
indicators. Control of glucose and cholesterol improved 
in both white patients and black patients.12 However, 
racial disparities in outcome measures widened because 
the improvements were greater for white patients. This 
shows that it is more difficult to improve outcomes than 
processes of care for disadvantaged populations.
If we are to identify persistent disparities between 
populations that will otherwise be masked by overall 
gains in quality, we need performance measures that are 
stratified by sex, ethnic origin, or socioeconomic status. 
In Canada, the project for an Ontario women’s health 
evidence based report card (POWER) is developing 
explicit methods for assessing equity as a routine part of 
performance measurement (www.powerstudy.ca).
In the US and the UK, practices that serve socio-
economically disadvantaged patients have shown 
poorer performance on commonly used quality indi-
cators than have practices serving more advantaged 
patients.13 14 Reporting these measures—particularly 
when pay is linked to performance—can inadvert-
ently penalise providers who care for those most in 
need, creating perverse incentives to exclude these 
patients. Risk adjustment models sometimes include 
socioeconomic status, but these can also mask real 
disparities in quality. An “equity blind” approach 
cannot account for the non-clinical factors that influ-
ence health outcomes, and it may stop us learning 
which components reduce disparities and which do 
not. Equity oriented performance measurement takes 
these factors into account, and it can make systems 
and providers publicly accountable for the communi-
ties they serve.
Indeed, performance measurement can be a bless-
ing, not a curse, for efforts to reduce inequities in 
quality. With adequate data, we can routinely meas-
ure and monitor progress, learn what tools and inter-
ventions work, develop and test new interventions 
to eliminate disparities, and understand a dimen-
sion of quality that has thus far seemed intractable. 
Ultimately, equity in health outcomes will probably 
be achieved only if we target the barriers that stop 
the providers serving disadvantaged patients and 
communities from reaching their quality targets. 
To investigate and eliminate disparities, we need to 
stratify performance data by the patients’ sex, ethnic 
origin, and other socioeconomic variables. This will 
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allow us to build an evidence base for implementing 
change that will maximise benefits and minimise harms. 
Equity must become an integral component of perform-
ance measurement.
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Involving patients in the BMJ
Another step towards achieving our goal of helping doctors make better decisions
The BMJ is a journal for doctors. Its mission is to 
to lead the debate on health and to engage, inform, 
and stimulate doctors, researchers, and other health 
professionals in ways that will improve outcomes 
for patients.
In recent years, patients and the public have 
become increasingly involved in shaping health 
care.1 2 In the UK, the government is promoting 
the inclusion of members of the public in strategic 
decisions about health services and policy at local 
and national level, and doctors are being encour-
aged to involve patients in treatment decisions. Most 
British medical royal colleges have established 
patient advisory groups and value those groups’ 
contributions to their work. Gradually, also, patients 
have been taking on more active teaching roles in 
medical training.3
Recognising this trend, the BMJ established its 
own patient advisory group in 2002 chaired by Mary 
Baker, a member of the BMJ’s editorial advisory 
board and president of the European Parkinson’s 
Disease Association. The group’s role is to help the 
BMJ achieve its mission to help doctors make better 
decisions. It does this by suggesting new content 
and commenting on the journal’s existing content in 
ways that will educate readers about patients’ needs. 
It began with a core of members mainly from the 
United Kingdom and from a few specialist areas 
(including cancer, dermatology, general practice, 
and medicines management).
Our plan now is to extend the group geographi-
cally and across more fields of medicine, to create 
a virtual group of patient advisers who will join the 
growing network of BMJ editorial advisers around 
the world.
Since the patient advisory group was formed 
patients have contributed editorials, commentaries, 
personal views, articles, and letters on a range of 
subjects. Perhaps their most obvious contribution 
has been through our intermittent series of patient 
journey articles—17 to date—which aim to help 
readers understand how a patient feels when 
confronting a difficult diagnosis, living with a 
chronic condition, or going through a traumatic 
medical event.
Doctors can, of course, be patients, too. Indeed, 
several patient journey articles have been written by 
clinicians who are themselves patients or carers.4 5 
Increasingly, patient journeys have been enhanced 
by the addition of commentaries from clinicians, 
which help identify and explain the lessons doctors 
can learn from them. We are always pleased to 
consider articles for this series.
Good writing is a hallmark of the BMJ, but people 
with interesting and worthwhile stories to tell should 
not be deterred from telling them just because they 
are not accomplished writers. The patient editor is 
always prepared to help authors, by advising on a 
manuscript’s potential and helping shape it to match 
the journal’s needs.
All this is just a starting point. We believe patients 
have far more to contribute to the BMJ than simply 
their own experiences of illness and treatment. Via 
the patient advisory group, we look forward to 
their input on matters as wide ranging as national 
health policy; the quality and direction of clinical 
research; healthcare inequalities; conundrums over 
the length and quality of life and quality of death; 
doctor-patient communication; the differences 
between treating disease and treating the patient; 
the respective values of anecdotal and research 
evidence; and the changing nature of society and 
its implications for health care. 
The redesign of the online and print versions 
of the BMJ should facilitate greater patient 
involvement. We will explore ways of achieving 
this, always bearing in mind that doctors 
are our main audience and that the clinical 
relevance and scientific quality of the journal’s 
content are paramount. We hope that you 
will welcome the increasing involvement of 
patients in the BMJ and that whatever specialty you 
work in, it will help you make better decisions for 
your patients.
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